Search
-
Ipsos Synthesio unveils Signals GenAI, providing instant consumer insights
Signals GenAI, our pioneering Generative AI platform app, empowers you to transform real-time consumer signals into actionable insights within 60 seconds. Now everyone can turn millions of consumer voices into actionable insights with just three simple clicks!
-
Beyond the Hype: Innovation predictions in the era of Machine Learning
Artificial intelligence (AI) has grown in popularity in recent years. Voice and facial recognition software is developed in all technical gadgets. In this context, we are also beginning to see how AI can also alter market research, resulting in faster, cheaper, and better results.
-
Artificial intelligence: Four points of vigilance
This article on AI from Helen Zeitoun, CEO Science Organisation and CEO Ipsos in France, was originally published in French in Strategies, March 2019.
-
Connected Health: A roadmap to success
Connected Health is moving into the mainstream – how will this change the traditional structure of healthcare?
-
Virtual Reality: Hype or the Future?
Virtual Reality (VR) technology has been around for at least a decade and you could say it’s clearly gone from sci-fi to sci-fact. However, it’s still seen as a new technology and has not hit mass adoption; so what has gone wrong?
-
Four Ways Agile Research Will Evolve to Drive Innovation
In today’s fast-moving, shape-shifting world, it seems virtually every business, every marketer, and every researcher wants to be agile. But, what exactly does agility mean?
-
Global Business Influencers 2017 Survey Launch
Global Business Influencers are the driving force behind business and investment decisions globally, leading their companies into a future where disruption is becoming the norm and technology is at the top of the agenda for many.
-
Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.